T. Rowe Price Associates
SEEL

T. Rowe Price Associates’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

T. Rowe Price Associates’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5
Closed -$47K – 2997
2021
Q2 		$47K Buy
+5
New +$82.2K ﹤0.01% 2901

Other funds holding SEEL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

T. Rowe Price Associates's SEEL Position: Q3 2021 in Review

T. Rowe Price Associates sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2021, closing a stake of 5 shares — an estimated $47K sold.

T. Rowe Price Associates first reported a position in SEEL in Q2 2021 and held it in 1 quarter. The position peaked at $47K in Q2 2021. 95 funds tracked by Wall St. Rank hold SEEL as of Q3 2021.

  • T. Rowe Price Associates reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 5 Seelos Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $47K.
  • T. Rowe Price Associates first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • T. Rowe Price Associates's Seelos Therapeutics, Inc. Common Stock position peaked at $47K in Q2 2021.
  • 95 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.